ProPhase Labs (NASDAQ:PRPH) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

ProPhase Labs, Inc. (NASDAQ:PRPH) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.26 and traded as low as $0.1661. ProPhase Labs shares last traded at $0.2799, with a volume of 1,509,825 shares changing hands.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wall Street Zen raised ProPhase Labs to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings restated a “sell (e+)” rating on shares of ProPhase Labs in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

ProPhase Labs Trading Down 22.8%

The business’s 50 day simple moving average is $1.78 and its 200-day simple moving average is $3.26. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14. The stock has a market capitalization of $1.68 million, a P/E ratio of -0.07 and a beta of -0.56.

ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings results on Wednesday, November 19th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.50). ProPhase Labs had a negative net margin of 825.01% and a negative return on equity of 482.05%. The company had revenue of $0.88 million during the quarter, compared to analyst estimates of $5.69 million. As a group, analysts forecast that ProPhase Labs, Inc. will post -1.27 EPS for the current year.

Hedge Funds Weigh In On ProPhase Labs

Institutional investors have recently modified their holdings of the stock. Sykon Capital LLC acquired a new stake in shares of ProPhase Labs in the 2nd quarter valued at approximately $252,000. Susquehanna International Group LLP increased its stake in ProPhase Labs by 290.1% in the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after purchasing an additional 295,899 shares in the last quarter. Accretive Wealth Partners LLC acquired a new stake in ProPhase Labs in the third quarter worth $114,000. Apollon Wealth Management LLC bought a new position in shares of ProPhase Labs during the third quarter worth $84,000. Finally, XTX Topco Ltd acquired a new position in shares of ProPhase Labs in the 2nd quarter valued at $40,000. 9.45% of the stock is currently owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.